Stay updated on P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.

Latest updates to the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page
- Check3 days agoChange DetectedThe page revision tag was updated from v3.6.0 to v3.6.2, indicating a software update to the page rendering. This likely reflects backend/frontend improvements and does not modify the study information.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedNew user guidance sections (How to Read a Study Record, Common Questions, How to Join a Study) and a recruitment-status note have been added. The Intervention/Treatment label remains visible and the revision version updated to v3.6.0, reflecting a refresh of the study details and navigation.SummaryDifference0.5%

- Check25 days agoChange DetectedThe page shows an updated revision label from v3.5.4 to v3.5.5, reflecting a version update rather than a change to the study details.SummaryDifference0.1%

- Check46 days agoChange DetectedThe page revision label was updated from v3.5.3 to v3.5.4, indicating a new release version; no substantive changes to the displayed study information are evident.SummaryDifference0.1%

- Check68 days agoChange DetectedThe page’s release/version indicator was updated from “Revision: v3.5.2” to “Revision: v3.5.3,” reflecting a maintenance or platform update rather than a change to the study content.SummaryDifference0.1%

- Check75 days agoChange DetectedAdded Revision: v3.5.2; Removed Revision: v3.5.0.SummaryDifference0.1%

Stay in the know with updates to P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the P53MVA & Pembrolizumab in Recurrent Ovarian Cancer Clinical Trial page.